[go: up one dir, main page]

ECSP17030050A - Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson - Google Patents

Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson

Info

Publication number
ECSP17030050A
ECSP17030050A ECIEPI201730050A ECPI201730050A ECSP17030050A EC SP17030050 A ECSP17030050 A EC SP17030050A EC IEPI201730050 A ECIEPI201730050 A EC IEPI201730050A EC PI201730050 A ECPI201730050 A EC PI201730050A EC SP17030050 A ECSP17030050 A EC SP17030050A
Authority
EC
Ecuador
Prior art keywords
parkinson
antagonist
disease
treatment
adhd
Prior art date
Application number
ECIEPI201730050A
Other languages
English (en)
Inventor
Nathalie Breysse
Lone Frydelund Larsen
Johan Areberg
Gamini Chandrasena
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP17030050A publication Critical patent/ECSP17030050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a dosis específicas de un antagonista de A2A para utilizarlo como un medicamento y, en particular, que sean útiles para el tratamiento de la enfermedad de Parkinson y del trastorno por déficit de atención con hiperactividad.
ECIEPI201730050A 2014-12-03 2017-05-16 Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson ECSP17030050A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
ECSP17030050A true ECSP17030050A (es) 2017-08-31

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201730050A ECSP17030050A (es) 2014-12-03 2017-05-16 Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (es)
EP (1) EP3226863A1 (es)
JP (1) JP2017536400A (es)
KR (1) KR20170090430A (es)
CN (1) CN106999480A (es)
AU (1) AU2015357197A1 (es)
BR (1) BR112017011777A2 (es)
CA (1) CA2966582A1 (es)
CL (1) CL2017001407A1 (es)
CO (1) CO2017004785A2 (es)
CR (1) CR20170221A (es)
DO (1) DOP2017000121A (es)
EA (1) EA201790973A1 (es)
EC (1) ECSP17030050A (es)
IL (1) IL252355A0 (es)
MA (1) MA41090A (es)
MX (1) MX2017007027A (es)
NI (1) NI201700066A (es)
PE (1) PE20170926A1 (es)
PH (1) PH12017500923A1 (es)
SG (1) SG11201704370XA (es)
SV (1) SV2017005441A (es)
TN (1) TN2017000174A1 (es)
TW (1) TW201632186A (es)
WO (1) WO2016087429A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629414T3 (es) * 2003-12-26 2017-08-09 Kyowa Hakko Kirin Co., Ltd. Derivados de tiazol
BRPI0916203A2 (pt) * 2008-07-23 2018-05-15 Kyowa Hakko Kirin Co Ltd agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
CO2017004785A2 (es) 2017-08-31
BR112017011777A2 (pt) 2018-02-20
EP3226863A1 (en) 2017-10-11
CN106999480A (zh) 2017-08-01
US20160158211A1 (en) 2016-06-09
PE20170926A1 (es) 2017-07-13
NI201700066A (es) 2018-01-04
TN2017000174A1 (en) 2018-10-19
CR20170221A (es) 2017-10-05
IL252355A0 (en) 2017-07-31
MX2017007027A (es) 2017-08-24
MA41090A (fr) 2017-10-10
DOP2017000121A (es) 2017-07-15
US20180125835A1 (en) 2018-05-10
WO2016087429A1 (en) 2016-06-09
SG11201704370XA (en) 2017-06-29
CA2966582A1 (en) 2016-06-09
EA201790973A1 (ru) 2017-10-31
TW201632186A (zh) 2016-09-16
KR20170090430A (ko) 2017-08-07
SV2017005441A (es) 2017-08-25
PH12017500923A1 (en) 2017-11-20
JP2017536400A (ja) 2017-12-07
CL2017001407A1 (es) 2018-01-05
AU2015357197A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
ECSP17030050A (es) Antagonista de A2A de dosis baja para el tratamiento de TDAH y la enfermedad de Parkinson
MX2017005064A (es) Metodos para tratar afecciones oculares.
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
BR112017016333A2 (pt) compostos anticâncer
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
EA201990181A1 (ru) Получение активированных клостридиальных нейротоксинов
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
PT3154597T (pt) Métodos de preparação para uma nova geração de produtos biológicos de klh seguros utilizados para o tratamento de cancro, para o desenvolvimento de de vacinas conjugadas terapêuticas e como agentes competitivos
UY34479A (es) Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112017003334A8 (pt) Variantes de desintegrina e usos farmacêuticos destas